《新股消息》华检医疗(01931.HK)明日起招股入场费3,717.08元
内地体外诊断产品分销商华检医疗(01931.HK)明日(29日)起招股,招股价介乎3.07-3.68元,每手1,000股,入场费3,717.08元,7月5日截止认购申请,预计7月12日挂牌,是次上市独家保荐人为中银国际亚洲。
公司今次发行3.33亿股,当中一成作公开发售,已招股价中位数3.38元计算,净筹10.31亿元,当中44.8%将用於结清收购威士达六成股权的现金代价之未偿还结余;29.8%用於根据股东协议向公司及威士达现有股东支付部份特别股息;9.9%用於扩大分销业务下的客户群;5.1%用於研发自有品牌产品;3.7%将用於扩展公司的分销业务及改善分销价值链;6.7%用作营运资金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.